Natixis Advisors L.P. Takes Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Natixis Advisors L.P. purchased a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 34,681 shares of the medical device company's stock, valued at approximately $1,025,000. Natixis Advisors L.P. owned approximately 0.05% of Tandem Diabetes Care as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Eminence Capital LP lifted its position in shares of Tandem Diabetes Care by 76.1% in the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company's stock worth $114,028,000 after buying an additional 2,372,458 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Tandem Diabetes Care by 252.6% in the third quarter. Jennison Associates LLC now owns 1,122,915 shares of the medical device company's stock worth $23,323,000 after buying an additional 804,488 shares during the last quarter. Banque Pictet & Cie SA acquired a new stake in shares of Tandem Diabetes Care in the third quarter worth about $2,295,000. Fred Alger Management LLC lifted its position in shares of Tandem Diabetes Care by 51.0% in the third quarter. Fred Alger Management LLC now owns 325,689 shares of the medical device company's stock worth $6,765,000 after buying an additional 110,049 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Tandem Diabetes Care by 79.5% in the fourth quarter. Russell Investments Group Ltd. now owns 247,325 shares of the medical device company's stock worth $7,316,000 after buying an additional 109,505 shares during the last quarter.

Wall Street Analysts Forecast Growth

TNDM has been the subject of a number of analyst reports. Barclays boosted their price target on Tandem Diabetes Care from $39.00 to $55.00 and gave the stock an "overweight" rating in a research report on Monday, May 6th. Leerink Partnrs raised Tandem Diabetes Care from a "market perform" rating to an "outperform" rating in a research report on Thursday, April 25th. SVB Leerink raised Tandem Diabetes Care from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $34.00 to $45.00 in a research report on Thursday, April 25th. StockNews.com raised Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research report on Friday, April 19th. Finally, Wells Fargo & Company raised Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $21.00 to $45.00 in a research report on Monday, April 29th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, Tandem Diabetes Care has a consensus rating of "Moderate Buy" and an average target price of $43.80.

Tandem Diabetes Care Price Performance

Shares of TNDM stock traded up $0.37 during trading hours on Friday, hitting $47.30. The company had a trading volume of 1,123,142 shares, compared to its average volume of 1,735,304. Tandem Diabetes Care, Inc. has a 12 month low of $13.82 and a 12 month high of $47.88. The firm has a market capitalization of $3.06 billion, a price-to-earnings ratio of -21.80 and a beta of 1.10. The firm's fifty day moving average is $35.59 and its 200 day moving average is $27.90. The company has a debt-to-equity ratio of 1.43, a quick ratio of 3.01 and a current ratio of 3.81.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The company had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. On average, sell-side analysts predict that Tandem Diabetes Care, Inc. will post -1.7 EPS for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.